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Abstract
Background: Older people have a high risk of vitamin B12 deficiency; this can lead to varying degrees of cognitive
and neurological impairment. CBL deficiency may present as macrocytic anemia, subacute combined degeneration
of the spinal cord, or as neuropathy, but is often asymptomatic in older people. Less is known about subclinical
vitamin B12 deficiency and concurrent neuroconduction and cognitive impairment. A Programme of
Complementary Feeding for the Older Population (PACAM) in Chile delivers 2 complementary fortified foods that
provide approximately 1.4 μg/day of vitamin B12 (2.4 μg/day elderly RDA). The aim of the present study is to
assess whether supplementation with vitamin B12 will improve neuroconduction and cognitive function in older
people who have biochemical evidence of vitamin B12 insufficiency in the absence of clinical deficiency.
Methods: We designed a cluster double-blind placebo-controlled trial involving community dwelling people aged
70-79 living in Santiago, Chile. We randomized 15 clusters (health centers) involving 300 people (20 per cluster).
Each cluster will be randomly assigned to one of three arms: a) a 1 mg vitamin B12 pill taken daily and a routine
PACAM food; b) a placebo pill and the milk-PACAM food fortified to provide 1 mg of vitamin B12; c) the routine
PACAM food and a placebo pill.
The study has been designed as an 18 month follow up period. The primary outcomes assessed at baseline, 4, 9
and 18 months will be: serum levels of vitamin B12, neuroconduction and cognitive function.
Conclusions: In view of the high prevalence of vitamin B12 deficiency in later life, the present study has potential
public health interest because since it will measure the impact of the existing program of complementary feeding
as compared to two options that provide higher vitamin B12 intakes that might potentially may contribute in
preserving neurophysiologic and cognitive function and thus improve quality of life for older people in Chile.
Trial registration: ISRCTN: ISRCTN02694183
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B12 is an essential micronutrient; in addition to its
known effects on red cell maturation it plays multiple
roles in metabolic pathways necessary for normal central
and peripheral nervous system function. B12 plays a key
role in one carbon metabolism (methyl group transfer)
necessary for neurotransmitter, choline, nucleotides, and
phospholipids synthesis [1]. Deficit is often seen in older
people [2], in association with age-related gastric atrophy,
low acid and intrinsic factor production resulting in
malabsorption of this micronutrient [3-8].
Serum concentrations of vitamin B12 > 221 pmol/dL
are considered normal, 148-221 pmol/dL corresponds to
subclinical deficit, and levels < 148 pmol/dL as deficiency.
B12 deficiency presents clinical with abnormal neurolo-
gic signs, cognitive loss, peripheral neuropathy and psy-
chiatric disorders. Sub-acute combined degeneration
(SCD) of the spinal cord is the classical pathological find-
ing of severe deficiency. Sensory polyneuropathy is also
observed in B12 deficiency. This neuropathy typically
involves preferentially large caliber afferent fibers [9]. If
these manifestations are treated early, most symptoms
disappear [10,11].
Clinical and electrophysiological features of sympto-
matic B12 deficiency with neurological manifestations
have been reported [12,13]. However, subclinical B12
deficiency is less well characterized, with few studies
and limited number of older people included [13,14].
This is relevant since population based surveys indicate
that the prevalence of B12 deficiency in people > 60
years is 6-20% [15].
A need for routine vitamin B12 supplementation in
older people in the absence of clinical deficit has not
been established. The OPEN Study is currently evaluating
the impact the B12 supplementation on neuroconduction
and cognitive function in older people [16].
Chile has undergone a period of rapid demographic
transition, which translates in an increase in the propor-
tion of older people. Studies in free-living older people
have been conducted in small groups of subjects; vitamin
B12 deficit in these groups ranges from 7-51% depending
on the definition of normal cut off values [17-19].
In an effort to promote healthy ageing, the Chilean
Health Ministry initiated in 1998 the Complementary
Feeding Programme for the Older Population (PACAM)
providing a nutritional supplement, rich in micronutrients,
to individuals ≥ 70 years registered at primary health cen-
ters. Since 2005, beneficiaries of PACAM receive B12 for-
tified foods providing approximately 1.7 μg/day, this is
equivalent to 71% RDA [6].
Despite the high acceptability and adherence to
PACAM by older people [20], vitamin B12 deficiency in
beneficiaries reaches 35%, suggesting that the amount
provided is low or that absorption is insufficient. There is
agreement that the oral administration of B12 raises
serum levels suggesting that there is a need to provide a
higher dose. Thus the aim of this study is to determine
whether the delivery of 1 mg vitamin B12 via PACAM
has similar effectiveness to oral administration of 1 mg
B12 as a pill; in terms of increasing serum levels, preser-
v i n gc o g n i t i v ef u n c t i o na n dn e u r o c o n d u c t i o ni no l d e r
people.
Design and methodology
The study is designed as a cluster double blind rando-
mized placebo-controlled trial to evaluate two modes of
high dose vitamin B12 delivery over an 18 months per-
iod in older people residing in Metropolitan Santiago,
Chile. Figure 1 and 2 illustrate schematically the flow
diagram for patient selection and procedures related to
this research study, full description is presented as
follows.
Study hypotheses
The study aims to test the following hypotheses.
1. The vitamin B12 dose provided by PACAM to older
people in Chile is insufficient to prevent vitamin B12
deficit and subclinical deficiency in the beneficiaries.
2. A dose (1 mg/day) of vitamin B12 intake provided
in a food supplement or as a pill will correct subclinical
deficiency vitamin B12 equally well, improving biomar-
kers of vitamin B12, cognitive function and neurocon-
duction in older people.
Criteria for Cluster Inclusion and Selection
In Chile, elderly beneficiaries of PACAM receive special
fortified foods through the National Health System pri-
mary health care centers. This trial was designed as a
public health programme effectiveness study, thus the
i n t e r v e n t i o n sw e r em a d ea v a i l a b l et h r o u g ht h ee s t a b -
lished health system under standard operating proce-
dures, without the use of resource-intensive
extraordinary efforts to secure uptake thus the design of
the intervention considered the health center as the clus-
ter unit for this study.
There are 94 health centers in Santiago Metropolitan
Area. Considering that the target population is older peo-
ple from low to medium socio-economic status, the nine
health centers located in higher income municipalities
were excluded. In order to facilitate data collection, health
centers with less than 400 people aged 70.0-79.9 registered
were excluded (n = 49) The geographic catchment areas
of the remaining 36 health centers were mapped, and fol-
lowing further discussions and site inspections, 15 health
centers were excluded because of insufficient interest
among health center staff (self-perception of having heavy
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health centers will be randomly selected and randomized,
to one of the three treatment arms.
The project statistician will randomize clusters into
the three study arms. Five centers will be included in
each arm, 20 individuals in each center. Randomization
will allow secure double blind allocation of center/clus-
ter to one of the 3 arms of the study. Following random
allocation a trial number will be given to each study
participant for further analysis. A subsample of eight
individuals will be randomly selected from each cluster
for neurophysiological function tests
  
Active PACAM beneficiaries from 15 
Health centres randomly selected from 94 in Santiago 
 
 
 
 
Pre-screen 4500 potential participants by phone contact: 70-79 years , 
healthy
1  free living/stable residence, not on vit B-12 injection/suplement 
 
                3800 excluded based on  
Initial pre-screen               
      
 
700 potential participants were interviewed at the health centre by research team to 
confirm pre-screen and request interim informed consent for (MMSE & Pfeffer) 
Initial baseline: evaluate health status, anthropometry, GDS15, diet, demographic 
status and socioeconomic level.  Schedule screening laboratory 
 
 
      
              Exclude if MMSE <20 and Pfeffer >5 
                                                                                               Does not meet entry criteria or 
                                                                                               refuses to participate                                     
 
 
Initial laboratory assessment: baseline blood sample taken 
 
Exclude if:                                                          
Fasting blood glucose ≥ 126 mg/dL,                  
     TSH ≥ 6.0 ml U/L                                        
                  Serum creatinine   ≥ 30 mg/mL         
B12 >700 pmol/L or < 120 pmol/L  
 
 
 
                                                 
1 Free from diabetes, renal insuficiency, hypothyroidism, , alcoholic, previous gastrointestinal surgery, 
cerebrovascular disease, and  unexplained weight loss of 3 kg in the last 3yrs 
Completed Baseline assessment: requested full informed consent.  
Random allocation of health centres (clusters)                        
5 centres in each of 3 study arm from each arm 40 subjects were 
randomly selected to perform Neurophysiology and Cognitive tests. 
 
 
Intervention 
Figure 1 Flow diagram for selection of participants, screening and baseline data collection.
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20 participants will be selected from each health center.
Potential participants will be identified from the center
registry.
Participants Inclusion criteria
People aged 70 to 79 years, with documented residence
and registration in the corresponding center where they
collect the PACAM foods.
Participant exclusion criteria
Phone calls will be used to identify and exclude those
who are not free living or have self-reported medical
conditions that increase susceptibility to vascular or
neurologic damage such as diabetes, renal insuficiency,
hypothyroidism, previous gastrointestinal surgery, cere-
brovascular disease or any terminal condition.
Individuals with unexplained weight loss of 3 kg in the
last 3 months and subjects who report use of vitamin
B12 injection in the last year or current supplements
will also be excluded.
Recruitment of participants
Potentially eligible individuals, after securing they have
no exclusion criteria by phone call; will receive an invi-
tation explaining the nature and relevance of the study
Initiate dietary intervention.   
Monthly distribution of milk based drink and pills. 
Fortified drink 
Placebo pill 
Unfortified drink 
B-12 pill 
Unfortified drink 
Placebo pill 
At 4 months: Blood sample (B-12 status) in all subjects.  
Neurophysiology in 40 per arm. 
At 9 months blood sample (B-12 status) in all subjects. 
Evaluate health status, anthropometry, MMSE, GDS15, diet, demographic 
status and socioeconomic level. 
At 18 months blood sample (B-12 status) in all subjects. 
Evaluate health status, anthropometry, MMSE, GDS15, diet 
Neurophysiology and cognitive testing  in 40 per arm. 
Completed Baseline assessment: requested full informed consent. 
Random allocation of health centres (clusters)                        
5 centres in each of 3 study arm from each arm 40 subjects were 
randomly selected to perform Neurophysiology and Cognitive tests. 
 (n=100 each) sub group n=40 per arm neurophysiology testing 
 
Figure 2 Follow up scheme.
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invitation will explicitly state that their refusal will not
affect in any way their access to, or the quality of, health
care they receive at the center. The research team will
confirm the absence of exclusion criteria at the time of
the health center interview, and will provide detailed
information about the nature and relevance of the study
a n dw h a tw i l lb ei n v o l v e di ft h e ya g r e et op a r t i c i p a t e .
Potential participants who manifest their interest will be
asked to complete a survey on diet and mental health,
and answer a short cognitive screen previously validated
in Chile consisting of the Mini Mental State Examina-
tion (MMSE) plus the Pffefer Activities Questionnaire
(PFAQ) [21]. Potential participants will have a MMSE
s c o r e>1 9( m a x i m u mo f3 0 )p l u saP F A Qs c o r el e s s
than six. Potential participants will be asked to give
informed consent and provide a blood sample and, if eli-
gible based on the results will be contacted. Those
unwilling to provide consent will be thanked for their
time and cooperation. Potential participants providing
full informed consent will be asked to provide a 13 ml
venous blood sample to assess serum vitamin B12,
hemoglobin, mean red cell volume (MCV), glucose,
TSH and serum creatinine concentrations. Blood sam-
ples will be sent to a central laboratory for analysis.
Serum will be kept to assay B12 status and serum folate
in the definitive participants. Eligible participants are
defined as those with fasting blood glucose < 126 mg/
dL, TSH < 6.0 mlU/L, creatinine clearance < 30 ml/min
(calculated using Cockcroft equation) [7], and serum
vitamin B12 120-700 pmol/L.
The research team will provide the results of the blood
tests to all potential participants. All eligible participants
will be contacted by phone by the study coordinator who
will restate the nature and relevance of the study and
what will be involved if they agree to take part. They will
be told that a prerequisite of their joining the study will
be that they agree to consume PACAM foods and a daily
tablet, and not receive any vitamin B12 injection over the
course of the study. They will be informed that non-
involvement will not prejudice the health care provision
from their general practice. At this point, potential parti-
cipants will be visited at home to give them the opportu-
nity to ask any questions before being invited to give full
informed consent to take part in the study.
A subsample of 120 subjects (8 per cluster, 40 per arm)
will undergo neurophysiological tests. The baseline tests
will be performed at the Department of Neurological
Sciences, Faculty of Medicine University of Chile. The full
battery will take approximately 75 minutes to complete.
The study manager will arrange private transportation for
the participant to attend the appointment. The use of pri-
vate transportation is expected to have a positive impact
on attendance and compliance rates. Individuals unwilling
to participate at the baseline hospital appointment, will be
thanked for their time and co-operation.
Intervention
A routine fortified food program provided monthly, deliv-
ered by the Chilean Ministry of Health under PACAM
through the health centers. The nutritional products are
1k go f“Años Dorados” (a cereal-legume and vegetable
powdered food) which provides 400 kcal/100 g and multi-
ple micronutrients (including 0,5 μg/100 g vitamin B12)
and 1 kg of “Bebida Láctea”, a micronutrient fortified
milk-based drink (including 2.8 μg/100 g vitamin B12)
monthly. The recommended serving size of these supple-
ments provides 1.4 μg daily corresponding to 58% of the
daily vitamin B12 recommended intake and 20% of daily
energy needed by older people [17]. Following the comple-
tion of baseline testing, participants will be introduced to
the intervention. All subjects in the three study arms will
receive both a pill and the food supplement in order to
maintain the double blind nature of the study. Each cen-
ter/cluster was randomly assigned to one of three arms:
one of the arms will receive a 1 mg vitamin B12 pill taken
daily and a routine PACAM food, a second arm will be
provided with a placebo pill and the “Bebida Lactea“
(milk-PACAM food fortified) to provide 1 mg of vitamin
B12 as consumed on a daily basis; finally a third arm will
receive the routine PACAM food and a placebo. The pill
will be identical in size, shape, color, smell and taste for
both the intervention and the placebo arms of the trial.
The intervention pill and the fortified milk base drink will
each contain 1 mg of B12.
We choose to fortify the milk delivered by the program,
given the higher adherence to “Bebida Lactea“ and “Años
Dorados“ by older people and the low intra-family dilution
of the products [22].
Adherence to the nutrition intervention is defined for
this study as collecting 1 kg per month of the fortified
food as documented by the health centers. Adherence for
the pill intervention will be monitored based on collection
of the pills supplement from the health center, 12 out of
18 months will be considered acceptable adherence Vita-
min B12 content of fortified and control Bebida Lactea
will be monitored in a sample randomly obtained at every
health center.
Outcome measures
Primary outcomes
Serum vitamin B12 status Serum vitamin B12 will be
assessed in duplicate at baseline, 4, 9 and 18 months by
t h eS i m u l T R A C _ S N Br a d i o a s s a yk i t(
57Co/Folate
125I)
(MP Diagnostics, Orangeburg, NY).
Peripheral nerve conduction Velocity conduction of
the right and left fibular nerve will be measured using
standard techniques at baseline, 4 and 18 months.
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(MMSE) is an easy to administer test, and has been vali-
dated for Chilean elderly. It will be performed at base-
line and at 18 months.
Secondary outcomes
Vitamin B12 status and serum folate Total homocys-
teine in plasma (tHcy), serum methyl malonic acid
(MMA), holo- transcobalamin (Holo-TC) and serum
folate will be assayed at baseline, 4, 9 and 18 months.
MMA will be analyzed by LC/MS/MS using a modifica-
tion of the method of Kushnir et al (18). Specifically, the
plasma aliquot is reduced from 1 mL to 25 mL and methyl
tert-butyl-ether (MTBE) is reduced from 3 mL to 0.4 mL,
allowing the use of disposable 1.5 mL microcentrifuge
tubes and eliminating the need for centrifugation. MMA
calibration standards (25-1000 nM) and d3-MMA surro-
gate (500 nM) are prepared in DI water and frozen until
use. Incubation is increased from 5 min at 50° to 30 min
at 60° to maximize derivatization efficiency. The chroma-
tographic interference between MMA and succinic acid
(SA) is removed (eliminating the need to correct MMA
for SA interference) by changing the mobile phase from
85% methanol and 15% 5 mM ammonium formate aqu-
eous buffer to 53% methanol and 47% 1.67 mM ammo-
nium formate, increasing the column temperature from
40° to 60°, reducing flow rate from 0.75 mL/min to
0.25 mL/min, and increasing the time between injections
from 1 min to 2 min. tHcy will be determined by HPLC
with a fluorescence detector (Agilent 1200, Santa Clara,
CA) and serum Hl-TC with the Axis Shield HoloTC RIA
(Axis-Shield Diagnostics Ltd., Dundee, UK). Analysis of
the blood samples will be the responsibility Department of
Agriculture, Agricultural Research Services, Western
Human Nutrition Research Center, Davis, CA, USA.
Blood samples will be couriered on dry ice in batches
from INTA, Santiago-Chile to Davis, California. Haemato-
logical and biochemical parameters will be assessed at
Micronutrients Laboratory, INTA, University of Chile.
Peripheral nerve conduction Nerve conduction studies
of the right and left sural, right and left tibial, right med-
ian and fibular nerves will be performed using standard
techniques at baseline, 4 and 18 months. Nerves will be
stimulated supramaximally at proximal and distal sites
and conduction velocity in the distal leg nerve segments
calculated. Supramaximal nerve stimuli are routinely
used daily to investigate neurological conditions with
minimal discomfort.
Neurological battery Evaluation includes sensory path-
ways of conduction of afferent sensory pathways of small
diameter, quantitative thermal and somatosensory
responses, specific neurosensory pathways and visual
evoked potential. All techniques will use surface electrodes
and limb temperature will be controlled to be above 30°C
by suitable heating and blankets and will be applied at
baseline, 4 and 18 months.
Visual evoked potentials (VEPs) VEPs (Nicolet Vicking
Quest) will be obtained using a checkerboard pattern
subtending an angle of 59 minutes of arc with a stimula-
tion rate of 2 Hz. The active electrode was at Oz with a
Cz reference and a ground at Fpz. Two trials of 200
responses were recorded for each eye. An upper limit of
120 msec will be considered as normal for the P100
potential (mean 2.5 SD).
Somatosensory evoked potentials (SSEPs) SSEPs will be
performed bilaterally in the median and tibial nerves. Sti-
mulus duration will be 0.1 msec. Median nerve SSEPs will
be recorded over the scalp (N20), in C3’/C4’-Fpz, on the
cervical spine (N13) and at the Erb point (N9). Central
conduction time (CCT) will be calculated between the cer-
vical spine and the contra lateral cortex (N13-N20). In our
laboratory the upper normal limit for CCT is 6.8 msec.
Tibial nerve SSEPs (N/P37) will be recorded at Cz’-Fpz
and in the popliteal region. Normality will be defined by a
cortical response with an absolute latency within 2.5 stan-
dard errors from height-latency regression line. Sensory
nerve conduction of both sural nerves will be performed
following conventional techniques.
Cognitive function Language ability will be assessed with
the Boston Naming Test, which has a range from 0 to 60.
Verbal memory will be evaluated from recall of ten words
from the battery developed by the Consortium to Establish
a Registry for Alzheimer’s disease (CERAD), testing
delayed recall and recognition. The score ranges from 0 to
10 and is repeated three times in each subject, for a possi-
ble maximum of 30 points. The Letters and Numbers test
from the WAIS-II-R evaluated working memory and the
Digit Symbol subtest (DSST) of the Wechsler Intelligence
Scale for Adults scored attention. Executive function will
be measured with the Stroop Test. The Geriatric Depres-
sion Scale (GDS-15) evaluated symptoms of depression,
defined as > 6 points. They will be performed at baseline
and 18 months.
Sample size
Based on the capacity to detect changes in serum vitamin
B12, MMSE and fibular nerve conduction velocity as the
main outcomes, a sample size of 300 individuals in total
(100 per arm) was calculated. In the case of serum vita-
min B12 (criteria for measuring efficacy at 4 mo and
effectiveness at 18 mo), the sample size was calculated
using Chi square statistical test to compare proportions.
We considered a frequency of vitamin B12 deficiency
(vitamin B12 < 221 pmol/L, IOM/USA criteria) of 41%,
in accordance with previous studies performed by our
group [23]. Considering that we will give a supplement of
1 mg of vitamin B12 per day, we expect a reduction of
Sánchez et al. Nutrition Journal 2011, 10:100
http://www.nutritionj.com/content/10/1/100
Page 6 of 9approximately 50% in the prevalence of vitamin B12 defi-
ciency in the intervention group. A sample size of 84 sub-
jects is required to detect a drop from 41% to 20,5% in
vitamin B12 deficiency in the intervention group, with a
significance of 95% (a: 0.05) and a power of 80% (b =
0.20),. Considering a possible loss of 15% at 18 months,
the number of subjects in each arm is 97. Using an intra-
cluster coefficient (ICC) of 0.0001 [24], and an estimated
number of 20 older adults per cluster, it will be necessary
to select 5 clusters per arm, corresponding to a total of
300 older adults.
The sample size for neuroconduction was based on
changes in velocity nerve conduction of fibular nerve (cri-
teria for measuring efficacy at 4 months and effectiveness
at 18 months). The calculation was performed using two
tailed student t test. We used a mean velocity of 44.3 ms
and a SD of 4.37 in accordance with previous studies per-
formed by our group. In order to detect an 8% change in
the velocity of conduction in the intervention group (con-
sidered clinically relevant), with a significance of 95% (a:
0.05) and a power of 90% (b =0 . 1 0 )as a m p l es i z eo f2 6
subjects is required. Considering a possible loss of 15% at
18 months, the number of subjects in each group is 30.
Using an ICC of 0.01499 obtained in a previous study and
an estimated number of 8 older adults per cluster, 4 clus-
ters per arm are necessary.
The sample size for the outcome MMSE scores (criteria
for measuring effectiveness) is based on a two-tailed stu-
dent t test. To detect an expected loss of 1.5 points in
MMSE score at 18 months with a significance of 95% (a:
0.05) and a power of 80% (b =0 . 2 0 )as a m p l es i z eo f4 4
subjects is required. The calculation was performed using
the average MMSE score of 27.0 and a SD of 2.5 in accor-
dance with previous studies performed by our group. Con-
sidering a possible loss of 15% at 18 months, the number
of subjects per each group was 51 older adults. Using an
ICC of 0.04171, obtained in a previous study and an esti-
mated number of 20 older adults per cluster, 5 clusters
per arm are necessary.
In summary, for the outcomes serum vitamin B12 and
MMSE 100 older people (5 clusters 20 people each) per
arm will be recruited. For the nerve conduction out-
come 40 older people (5 clusters 8 people each) per arm
will be recruited.
Trial monitoring
The main aim of monitoring is to ensure that partici-
pants adhere to the study, and secondly to minimize
attrition. A field worker will call the participants by tele-
phone every 2 weeks during the first 4 months of follow
up (8 calls in total), this will serve to remind participants
of the importance of study and the need to comply with
the regular consumption of products.
Assessment at baseline, 4, 9 and 18 months
All participants will be assessed for:
1. CBL status and serum folate: as at baseline, 4 m,
9m ,1 8m
2. Nerve conduction: as at baseline, 4 m, 18 m
3. Clinical markers of neurological function: as at
baseline, 4 m and 18 m
4. Cognitive health: as at baseline, 18 m
5. Anthropometry: as at baseline, 9 m, 18 m.
Data analysis
Statisticians at INTA will conduct data analysis; all
involved in this analysis will be blind to the treatment
allocation. At the end of the interventions, primary ana-
lyses will be carried out based on the groups as rando-
mized (“intention to treat”). Results will be presented as
appropriate effect sizes with a measure of precision (95%
confidence intervals). All analyses will take account of
the clustered design. Covariates will be adjusted for in
t h ea n a l y s i sa sn e c e s s a r y .F u r ther exploratory analyses
will be based on those participants who fully follow the
various treatment protocols (“per-protocol analyses”).
Ethical approval
The Institutional Review Board at INTA, University of
Chile, approved the protocol for this study.
Trial organization
Investigators
1. Hugo Sánchez: epidemiologist based at INTA, Univer-
sity of Chile.
2. Cecilia Albala: senior geriatric epidemiologist based
at INTA, University of Chile.
3. Eva Hertrampf: senior haematologist based at
INTA, University of Chile.
4. José Luis Castillo: clinical neurologist based at
Department of Neurology, Faculty of Medicine, Univer-
sity of Chile.
5. Renato Verdugo: clinical neurologist based at
Department of Neurology, Faculty of Medicine, Univer-
sity of Chile.
6. Manuel Lavados: clinical neurologist based at
Department of Neurology, Faculty of Medicine, Univer-
sity of Chile.
7. Lydia Lera: statistician based at INTA, University of
Chile.
8. Alex Brito: nutritionist based at INTA, University of
Chile.
9. Lindsay Allen: senior public health nutritionist
b a s e da tD e p a r t m e n to fA g r i c u l t u r e ,A g r i c u l t u r a l
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Page 7 of 9Research Services, Western Human Nutrition Research
Center, Davis, CA, USA.
10. Ricardo Uauy (Principal Investigator PI): senior
public health nutritionist based at INTA, University of
Chile and Department of Nutrition and Public Health
Intervention Research, Faculty of Epidemiology and
Population Health, London School of Hygiene & Tropi-
cal Medicine, London, UK.
Project Management Group
A Project Management Group (comprising principal
investigators, trial manager, research nurses, database
manager and statistician) will run the trial on a day-to-
day basis to ensure the smooth operation of the project.
Regular review meetings will be held with other mem-
bers of the team as appropriate.
Publication Policy
The protocol and the primary results of the trial will be
published with authorship in relation to specific partici-
pation in the study, with name order to be presented by
the PI. Suggested revisions in order of authors will meet
approval of the PI. Co-investigators in their area of
expertise subject and the PI will lead publications in
specific areas of the study or on methodological aspects.
The requirements for authorship will follow recom-
mended practice in journal guidelines.
Confidentiality
All the research team, including practice staff, will be
made aware of the need for full confidentiality when deal-
ing with patient information; participants will be identified
by their study number to ensure confidentiality. However,
as the participants in the study will be followed up for
18 months following randomization, it is essential that the
teams at INTA and the Department of Neurology, Univer-
sity of Chile have a record of their names and addresses in
addition to the allocated trial number. Stringent precau-
tions will be taken to ensure confidentiality of participant’s
names and addresses. The investigators and local coordi-
nators will ensure that records are kept confidential and
access is restricted.
Sponsor
The Institute of Nutrition and Food Technology and the
Department of Neurology at University of Chile will act
as the main sponsors for this study. Delegated responsi-
bilities will be assigned locally.
Conclusion
Vitamin B12 deficiency is common in older people, it can
often be asymptomatic or present with clinical signs of
deficiency. The current trial is designed to test the hypoth-
esis that subclinical deficiency vitamin B12 is associated
with impaired cognition and neuroconduction in older
people. This study will reveal whether a daily high-dose of
vitamin B12 will correct and prevent deficiency, will mod-
ify biomarkers of vitamin B12 status and will attenuate
cognitive decline and impaired neuroconduction in older
people.
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States Department of Agriculture; SAP: Sensory action potential; MMA:
Serum methyl malonic acid; SSEPs: Somatosensory evoked potentials; TSH:
Thyroid stimulating hormone; tHcy: Total Homocysteine; VEPs: Visual evoked
potentials.
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